Evidence Hub

Formulation & evaluation of empagliflozin tablet in diabetes mellitus

Varsha Prajapat

TMP Universal Journal of Advances in Pharmaceutical Sciences, 2025

Abstract

Diabetes mellitus is a long-term metabolic disorder marked by elevated blood glucose levels and associated complications. Empagliflozin, a sodium–glucose co-transporter-2 (SGLT-2) inhibitor, lowers plasma glucose by reducing renal glucose reabsorption and is widely prescribed for type-2 diabetes management. The objective of the present investigation was to develop and evaluate an oral tablet formulation of empagliflozin with acceptable quality attributes. Tablets were prepared using the direct compression technique and appropriate pharmaceutical excipients. Pre-compression studies were conducted to assess powder flow characteristics, including bulk density, tapped density, angle of repose, Carr’s index, and Hausner’s ratio. The compressed tablets were evaluated for physicochemical parameters such as weight variation, hardness, friability, thickness, disintegration time, drug content uniformity, and

in-vitro drug release. The optimized formulation demonstrated satisfactory mechanical strength, uniform drug distribution, rapid disintegration, and consistent dissolution behavior. Stability assessment confirmed the formulation’s integrity, indicating its suitability for effective oral therapy in diabetes mellitus.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free